MA34519B1 - Anticorps anti-fap et procédés d'utilisation - Google Patents

Anticorps anti-fap et procédés d'utilisation

Info

Publication number
MA34519B1
MA34519B1 MA35725A MA35725A MA34519B1 MA 34519 B1 MA34519 B1 MA 34519B1 MA 35725 A MA35725 A MA 35725A MA 35725 A MA35725 A MA 35725A MA 34519 B1 MA34519 B1 MA 34519B1
Authority
MA
Morocco
Prior art keywords
methods
fap antibodies
fap
antibodies
relates
Prior art date
Application number
MA35725A
Other languages
English (en)
Inventor
Marina Bacac
Anne Freimoser-Grundschober
Ralf Hosse
Christian Klein
Ekkehard Moessner
Valeria G Nicolini
Pablo Umana
Original Assignee
Roche Glycart Ag
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44629814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34519(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag, Hoffmann La Roche filed Critical Roche Glycart Ag
Publication of MA34519B1 publication Critical patent/MA34519B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plant Pathology (AREA)

Abstract

La présente invention concerne des anticorps dirigés contre la protéine d'activation des fibroblastes (FAP) et des procédés d'utilisation de ceux-ci.
MA35725A 2010-08-13 2011-08-09 Anticorps anti-fap et procédés d'utilisation MA34519B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10172842 2010-08-13
PCT/EP2011/063648 WO2012020006A2 (fr) 2010-08-13 2011-08-09 Anticorps anti-fap et procédés d'utilisation

Publications (1)

Publication Number Publication Date
MA34519B1 true MA34519B1 (fr) 2013-09-02

Family

ID=44629814

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35725A MA34519B1 (fr) 2010-08-13 2011-08-09 Anticorps anti-fap et procédés d'utilisation

Country Status (37)

Country Link
US (5) US9011847B2 (fr)
EP (2) EP2603530B1 (fr)
JP (4) JP5793568B2 (fr)
KR (2) KR101780131B1 (fr)
CN (2) CN103154038B (fr)
AR (2) AR082629A1 (fr)
AU (1) AU2011288487B2 (fr)
BR (1) BR112013003361B8 (fr)
CA (1) CA2806021C (fr)
CL (2) CL2013000369A1 (fr)
CO (1) CO6670523A2 (fr)
CR (2) CR20180142A (fr)
DK (1) DK2603530T3 (fr)
EA (2) EA037977B1 (fr)
EC (1) ECSP13012440A (fr)
ES (1) ES2655616T3 (fr)
HK (1) HK1181402A1 (fr)
HR (1) HRP20172004T1 (fr)
HU (1) HUE036077T2 (fr)
IL (2) IL224355B (fr)
LT (1) LT2603530T (fr)
MA (1) MA34519B1 (fr)
MX (1) MX358859B (fr)
MY (2) MY175341A (fr)
NO (1) NO2603530T3 (fr)
NZ (2) NZ703653A (fr)
PE (2) PE20171512A1 (fr)
PH (1) PH12017501417A1 (fr)
PL (1) PL2603530T3 (fr)
PT (1) PT2603530T (fr)
RS (1) RS56702B1 (fr)
SG (1) SG187746A1 (fr)
SI (1) SI2603530T1 (fr)
TW (2) TWI556827B (fr)
UA (2) UA113712C2 (fr)
WO (1) WO2012020006A2 (fr)
ZA (2) ZA201600551B (fr)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2483310T3 (da) 2009-09-29 2014-09-01 Roche Glycart Ag Bispecifik dødsreceptor-agonistiske antistoffer
NZ703653A (en) * 2010-08-13 2016-09-30 Roche Glycart Ag Anti-fap antibodies and methods of use
UA117294C2 (uk) 2011-02-10 2018-07-10 Рош Глікарт Аг Імунокон'югат
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2013026839A1 (fr) 2011-08-23 2013-02-28 Roche Glycart Ag Anticorps bispécifiques spécifiques pour les antigènes d'activation des lymphocytes t et un antigène tumoral et procédés d'utiliation correspondants
NO2748201T3 (fr) 2011-08-23 2018-05-12
RS57744B1 (sr) 2011-08-23 2018-12-31 Roche Glycart Ag Bispecifični antigen vezujući molekuli
SG10201800535XA (en) * 2012-08-07 2018-02-27 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
WO2014023673A1 (fr) 2012-08-08 2014-02-13 Roche Glycart Ag Protéines de fusion de l'interleukine-10 et leurs utilisations
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US10087250B2 (en) 2012-10-08 2018-10-02 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
CA2896370A1 (fr) 2013-02-26 2014-09-04 Roche Glycart Ag Molecules bispecifiques de liaison a l'antigene activant les lymphocytes t
MX2015010843A (es) 2013-02-26 2016-04-04 Roche Glycart Ag Moleculas biespecificas de union al antigeno que activan celulas t.
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2015117930A1 (fr) * 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Immunoconjugués d'interleukine 10
GB201402006D0 (en) * 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
SI3102595T1 (sl) 2014-02-06 2019-02-28 F. Hoffmann-La Roche Ag Fuzijske beljakovine z interlevkinom-2 in njihova uporaba
EP3134115A4 (fr) 2014-04-25 2017-10-25 The Trustees Of The University Of Pennsylvania Procédés et compositions pour le traitement du cancer du sein métastatique et d'autres cancers dans le cerveau
DK3142750T3 (da) 2014-05-13 2020-09-14 Univ Pennsylvania Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf
JP6810687B2 (ja) * 2014-10-08 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｆａｐ及びｄｒ５に特異的な二重特異性抗体と化学療法剤との併用療法
CN113372434B (zh) 2014-11-14 2024-06-04 豪夫迈·罗氏有限公司 包含tnf家族配体三聚体的抗原结合分子
EP3789402B1 (fr) 2014-11-20 2022-07-13 F. Hoffmann-La Roche AG Thérapie de combinaison de molécules de liaison à l'antigène bispécifiques d'activation des lymphocytes t et d'antagonistes de liaison à l'axe pd-1
WO2016110598A1 (fr) * 2015-01-09 2016-07-14 Mabimmune Diagnostics Ag Nouveaux anticorps anti-protéine d'activation des fibroblastes (fap) et utilisations de ceux-ci
GB201500875D0 (en) * 2015-01-19 2015-03-04 Philogen Spa Antibodies for treatment and diagnosis
EP3277305B1 (fr) 2015-03-31 2021-07-21 F. Hoffmann-La Roche AG Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MA43017A (fr) * 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
JP6622392B2 (ja) 2015-10-02 2019-12-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ１とｔｉｍ３に特異的な二重特異性抗体
CN106928368B (zh) * 2015-12-30 2020-10-13 广西医科大学 一种FAP纳米抗体Nb57
EP3231813A1 (fr) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Molécules de liaison d'antigène costimulantes trimères contenant un ligand de la famille du tnf
JP7285076B2 (ja) 2016-05-11 2023-06-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｔｎｆファミリーリガンドトリマーとテネイシン結合部分とを含む抗原結合分子
EP3243836A1 (fr) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG Molécules de liaison à un antigène contenant un trimère d'un ligand de la famille du tnf fusionné en terminaison c
EP3243832A1 (fr) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf et un fragment de liaison pd1
CN106018780B (zh) * 2016-05-17 2017-12-26 扬州大学 一种基于f1蛋白的检测4型禽腺病毒抗体的间接免疫荧光试剂盒
JP7012668B2 (ja) 2016-06-12 2022-02-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ジヒドロピリミジニルベンズアゼピンジカルボキサミド化合物
EP3478321A4 (fr) 2016-06-30 2020-04-22 Oncorus, Inc. Administration par un virus oncolytique pseudotypé de polypeptides thérapeutiques
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
WO2018114754A1 (fr) 2016-12-19 2018-06-28 F. Hoffmann-La Roche Ag Polythérapie avec des agonistes de 4-1bb (cd137) ciblés
ES2847973T3 (es) 2016-12-20 2021-08-04 Hoffmann La Roche Politerapia de anticuerpos biespecíficos anti-CD20/anti-CD3 y agonistas de 4-1BB (CD137)
MX2019007795A (es) 2017-01-03 2019-08-16 Hoffmann La Roche Moleculas de union a antigeno biespecificas que comprenden el clon 20h4.9 anti-4-1bb.
WO2018129497A1 (fr) 2017-01-09 2018-07-12 Bioxcel Therapeutics, Inc. Procédés prédictifs et diagnostiques pour le cancer de la prostate
JP7196094B2 (ja) 2017-03-29 2022-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
WO2018178074A1 (fr) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Molécules trimériques de liaison à l'antigène spécifiques pour récepteur de co-stimulation du tnf
CN110382542B (zh) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
RS63663B1 (sr) 2017-04-03 2022-11-30 Hoffmann La Roche Imunokonjugati anti-pd-1 antitela sa mutantom il-2 ili sa il-15
RU2766234C2 (ru) * 2017-04-04 2022-02-10 Ф. Хоффманн-Ля Рош Аг Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
CA3052532A1 (fr) 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Anticorps bispecifiques se liant particulierement a pd1 et lag3
CN110505883A (zh) 2017-04-13 2019-11-26 豪夫迈·罗氏有限公司 供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
CN111132998B (zh) 2017-09-25 2024-01-30 苏州丁孚靶点生物技术有限公司 用于癌症治疗的方法和组合物
WO2019067425A1 (fr) 2017-09-26 2019-04-04 The Trustees Of The University Of Pennsylvania Compositions et procédés pour traiter une maladie cardiaque par des immunothérapies à lymphocytes t redirigés
US20210324108A1 (en) * 2017-11-01 2021-10-21 Hoffmann-La Roche Inc. Bispecific 2+1 contorsbodies
TW201930353A (zh) 2017-11-01 2019-08-01 瑞士商赫孚孟拉羅股份公司 使用經靶向之ox40促效劑的組合療法
JP2021500902A (ja) 2017-11-01 2021-01-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
CN109796532B (zh) 2017-11-17 2024-09-10 恺兴生命科技(上海)有限公司 靶向成纤维激活蛋白α的结合单元及其应用
EP3502140A1 (fr) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Thérapie de combinaison d'agonistes d'icos ciblés contre la tumeur avec des molécules bispécifiques à cellules t
WO2019133847A1 (fr) 2017-12-29 2019-07-04 Oncorus, Inc. Administration par un virus oncolytique de polypeptides thérapeutiques
KR20200128533A (ko) * 2018-02-05 2020-11-13 오리오니스 바이오사이언시즈 인코포레이티드 섬유아세포 결합제 및 이의 용도
BR112020015568A2 (pt) 2018-03-13 2020-12-29 F. Hoffmann-La Roche Ag Agonista de 4-1bb (cd137), produto farmacêutico, composição farmacêutica, uso de uma combinação de um agonista de 4-1bb e método para tratar ou retardar a progressão do câncer
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
EP3773911A2 (fr) 2018-04-04 2021-02-17 Xencor, Inc. Anticorps hétérodimères qui se lient à la protéine d'activation des fibroblastes
PE20210652A1 (es) 2018-04-13 2021-03-26 Hoffmann La Roche Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
BR112020023299A2 (pt) * 2018-05-16 2021-02-02 Dragonfly Therapeutics, Inc. proteína de ligação nkg2d, cd16 e uma proteína de ativação de fibroblastos
TW202035447A (zh) 2018-07-04 2020-10-01 瑞士商赫孚孟拉羅股份公司 新穎雙特異性促效性4-1bb抗原結合分子
MA53806A (fr) * 2018-10-01 2022-01-05 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène comprenant un clone anti-fap 212
JP2022511396A (ja) 2018-10-01 2022-01-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ４０への三価結合を伴う二重特異性抗原結合分子
SG11202105093RA (en) 2018-12-21 2021-06-29 Hoffmann La Roche Tumor-targeted agonistic cd28 antigen binding molecules
TW202030204A (zh) 2018-12-21 2020-08-16 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之超促效cd28抗原結合分子
WO2020208049A1 (fr) 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Molécules bispécifiques de liaison à un antigène comprenant des mutéines de lipocalines
JP2022538075A (ja) 2019-06-26 2022-08-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体結合ｃｅａ及び４－１ｂｂｌの融合
EP3990492A1 (fr) 2019-06-27 2022-05-04 F. Hoffmann-La Roche AG Nouveaux anticorps anti-icos et molécules de liaison à un antigène ciblant les tumeurs les comprenant
CN118406106A (zh) 2019-07-08 2024-07-30 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
CN114341158B (zh) 2019-07-08 2024-08-06 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
EP3763726A1 (fr) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Composés comprenant un ligand de protéine d'activation de fibroblastes et leur utilisation
CN114746438A (zh) 2019-09-23 2022-07-12 宾夕法尼亚大学董事会 通过靶向成纤维细胞激活蛋白(fap)使肿瘤组织破裂
CN114761036A (zh) * 2019-09-23 2022-07-15 宾夕法尼亚大学董事会 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体
EP4087657A1 (fr) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Conjugués inhibiteurs d'alk5 et leurs utilisations
WO2021140130A1 (fr) 2020-01-09 2021-07-15 F. Hoffmann-La Roche Ag Nouvelles molécules de liaison à l'antigène contenant un trimère de 4-1bbl
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
AU2021272340A1 (en) 2020-05-11 2022-12-08 F. Hoffmann-La Roche Ag Combination therapy with modified pbmcs and an immunoconjugate
WO2021257808A2 (fr) * 2020-06-17 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Anticorps dirigés contre la protéine d'activation des fibroblastes et b7h3
CR20220627A (es) 2020-06-23 2023-02-17 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se derigen a her2
JP2023531067A (ja) 2020-06-25 2023-07-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子
CN112540176B (zh) * 2020-07-08 2021-09-28 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质
KR20230066552A (ko) 2020-07-24 2023-05-16 에프. 호프만-라 로슈 아게 항체-다량체-융합체의 발현 방법
EP4198050A4 (fr) 2020-08-11 2024-05-01 Kanaph Therapeutics Inc. Protéine de fusion comprenant il-12 et un anticorps anti-cd20 et utilisation associée
CN117916261A (zh) 2020-11-16 2024-04-19 豪夫迈·罗氏有限公司 与靶向fap的cd40激动剂的组合疗法
IL303925A (en) 2021-01-07 2023-08-01 3B Pharmaceuticals Gmbh Compounds comprising a protein ligand for fibroblast activation and its use
EP4050018A1 (fr) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Composés comprenant un ligand de protéine d'activation de fibroblastes et leur utilisation
EP4314032A1 (fr) 2021-03-30 2024-02-07 F. Hoffmann-La Roche AG Polypeptides activés par une protéase
WO2023113806A1 (fr) 2021-12-16 2023-06-22 Affinia Therapeutics, Inc. Vaa recombinant pour le traitement d'une maladie neurale
EP4323531A1 (fr) 2021-04-12 2024-02-21 Affinia Therapeutics Inc. Aav recombinant pour le traitement d'une maladie neurale
WO2022223824A1 (fr) * 2021-04-23 2022-10-27 Philogen S.P.A Anticorps anti-protéine d'activation des fibroblastes
WO2022232289A1 (fr) 2021-04-27 2022-11-03 Generation Bio Co. Vecteurs d'adn non viraux exprimant des anticorps thérapeutiques et leurs utilisations
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
EP4148067A1 (fr) 2021-09-08 2023-03-15 F. Hoffmann-La Roche AG Procédé d'expression d'une fusion anticorps-multimère
TW202325742A (zh) 2021-11-01 2023-07-01 瑞士商赫孚孟拉羅股份公司 使用 HLA-A2/WT1 x CD3 雙特異性抗體及 4-1BB (CD137) 促效劑治療癌症
WO2023110788A1 (fr) 2021-12-14 2023-06-22 F. Hoffmann-La Roche Ag Traitement du cancer à l'aide d'un anticorps bispécifique hla-a2/mage-a4 x cd3 et d'un agoniste de 4-1bb (cd137)
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
MX2024009564A (es) 2022-02-11 2024-08-19 Kanaph Therapeutics Inc Composicion farmaceutica para tratamiento de cancer que comprende proteina de fusion que incluye il-12 y anticuerpo anti-fap, y uso de la misma.
AU2023235112A1 (en) 2022-03-14 2024-10-17 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
WO2023186756A1 (fr) 2022-03-28 2023-10-05 F. Hoffmann-La Roche Ag Variants d'interféron gamma et molécules de liaison à l'antigène les comprenant
CN114685673A (zh) * 2022-03-29 2022-07-01 深圳医爱健康管理有限公司 成纤维细胞激活蛋白抗体及使用方法
WO2024027771A1 (fr) * 2022-08-03 2024-02-08 南京维立志博生物科技有限公司 Protéine de fusion d'anticorps ciblant fap et tgfβ, et son utilisation
WO2024074727A1 (fr) 2022-10-07 2024-04-11 Genethon Immunothérapie cellulaire par car-t anti-fap pour traiter des myopathies squelettiques
WO2024120199A1 (fr) * 2022-12-08 2024-06-13 Analytical Biosciences Shanghai Limited Anticorps bispécifiques/multi-spécifiques et leurs utilisations
WO2024184287A1 (fr) 2023-03-06 2024-09-12 F. Hoffmann-La Roche Ag Polythérapie à base d'un anticorps anti-egfrviii/anti-cd3 et d'un agoniste de 4-1bb ciblant une tumeur
WO2024188966A1 (fr) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Traitement du cancer à l'aide d'un anticorps bispécifique anti-hla-g/anti-cd3 et d'un agoniste de 4-1bb (cd137)
WO2024208777A1 (fr) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag Anticorps agonistes tout-en-un
WO2024208776A1 (fr) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag Anticorps split agonistes
CN118496382A (zh) * 2024-05-22 2024-08-16 山东第一医科大学附属省立医院(山东省立医院) 一种靶向fap的嵌合抗原受体、car-t细胞及其在肝纤维化中的应用

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
EP0368684B2 (fr) 1988-11-11 2004-09-29 Medical Research Council Clonage de séquences d'immunoglobulines de domaines variables.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (fr) 1989-10-25 2006-02-07 Ravi J. Chari Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
AU2782292A (en) 1991-09-18 1993-04-27 Sloan-Kettering Institute For Cancer Research Activated stromal fibroblast-specific antibody, f19 and methods of using the same
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
EP0714409A1 (fr) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Anticorps
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1028751B1 (fr) 1997-10-31 2008-12-31 Genentech, Inc. Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP0953639A1 (fr) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH Anticorps dirigé contre FAPalpha pouvant être produit avec une efficacité accrue
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
NZ517906A (en) 1999-10-04 2003-01-31 Medicago Inc Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
IL149809A0 (en) 1999-12-15 2002-11-10 Genentech Inc Shotgun scanning, a combinatorial method for mapping functional protein epitopes
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
WO2001068708A2 (fr) 2000-03-17 2001-09-20 Boehringer Ingelheim Pharma Kg ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a)
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
JP4936299B2 (ja) 2000-08-21 2012-05-23 メレクシス・テクノロジーズ・ナムローゼフェンノートシャップ 磁場方向検出センサ
EA013224B1 (ru) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1916303B1 (fr) 2000-11-30 2013-02-27 Medarex, Inc. Acides nucléiques codant des séquences d'immunoglobulines humaines réarrangées obtenus de souris transgéniques chromosomales
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
ES2402527T3 (es) 2001-12-27 2013-05-06 Glycofi, Inc. Procedimientos para obtener estructuras de carbohidrato de tipo mamífero mediante ingeniería genética
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003085118A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
CA2481658A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fcy iiia
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
WO2003084569A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
EP1513879B1 (fr) 2002-06-03 2018-08-22 Genentech, Inc. Bibliotheques de phages et anticorps synthetiques
SI1539966T1 (sl) 2002-09-12 2010-10-29 Greenovation Biotech Gmbh Postopek za produkcijo proteinov
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2301966A1 (fr) 2002-12-16 2011-03-30 Genentech, Inc. Variantes de l'immunoglobuline et leurs utilisations
CA2549932C (fr) 2002-12-20 2013-08-20 Greenovation Biotech Gmbh Ameliorations apportees ou associees a la production de proteines
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
CA2510003A1 (fr) 2003-01-16 2004-08-05 Genentech, Inc. Banques de phages anticorps synthetiques
ES2542885T3 (es) 2003-01-22 2015-08-12 Roche Glycart Ag Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2542046A1 (fr) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Composition proteique hybride
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
LT2348051T (lt) 2003-11-05 2019-02-25 Roche Glycart Ag Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2005053742A1 (fr) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition a base d'anticorps
WO2005097832A2 (fr) 2004-03-31 2005-10-20 Genentech, Inc. Anticorps anti-tgf-$g(b) humanises
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2357201B1 (fr) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anticorps dirigés contre la sélectine P
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2465870A1 (fr) 2005-11-07 2012-06-20 Genentech, Inc. Polypeptides de liaison dotés de séquences hypvervariables VH/VL diversifiées et consensuelles
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP1806365A1 (fr) * 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués
AR060871A1 (es) 2006-05-09 2008-07-16 Genentech Inc Union de polipeptidos con supercontigos optimizados
EP2471816A1 (fr) 2006-08-30 2012-07-04 Genentech, Inc. Anticorps multi-spécifiques
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
WO2011020783A2 (fr) * 2009-08-17 2011-02-24 Roche Glycart Ag Immunoconjugués ciblés
DK2483310T3 (da) 2009-09-29 2014-09-01 Roche Glycart Ag Bispecifik dødsreceptor-agonistiske antistoffer
AU2010301105A1 (en) * 2009-10-02 2012-04-19 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
NZ703653A (en) * 2010-08-13 2016-09-30 Roche Glycart Ag Anti-fap antibodies and methods of use
UA117294C2 (uk) 2011-02-10 2018-07-10 Рош Глікарт Аг Імунокон'югат
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
SG10201800535XA (en) 2012-08-07 2018-02-27 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
WO2014023673A1 (fr) 2012-08-08 2014-02-13 Roche Glycart Ag Protéines de fusion de l'interleukine-10 et leurs utilisations
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
MX2015014538A (es) 2013-05-07 2016-02-05 Hoffmann La Roche Moleculas de union a antigenos trimericas.
JP6810687B2 (ja) 2014-10-08 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｆａｐ及びｄｒ５に特異的な二重特異性抗体と化学療法剤との併用療法

Also Published As

Publication number Publication date
IL244000A0 (en) 2016-04-21
CL2016002116A1 (es) 2017-05-12
BR112013003361A2 (pt) 2017-06-13
CN105884898B (zh) 2022-10-11
ES2655616T3 (es) 2018-02-20
PT2603530T (pt) 2018-01-09
UA113712C2 (xx) 2017-02-27
US11332545B2 (en) 2022-05-17
HK1181402A1 (zh) 2013-11-08
ZA201600552B (en) 2017-03-29
MY184879A (en) 2021-04-29
RS56702B1 (sr) 2018-03-30
NZ703653A (en) 2016-09-30
BR112013003361B1 (pt) 2021-10-13
NO2603530T3 (fr) 2018-04-07
KR101780131B1 (ko) 2017-09-19
DK2603530T3 (en) 2018-01-15
CN105884898A (zh) 2016-08-24
US20160060357A1 (en) 2016-03-03
US9011847B2 (en) 2015-04-21
EP3333194A1 (fr) 2018-06-13
PL2603530T3 (pl) 2018-03-30
CN103154038B (zh) 2016-05-11
CA2806021C (fr) 2019-05-21
NZ605980A (en) 2015-01-30
AU2011288487A1 (en) 2013-01-31
CA2806021A1 (fr) 2012-02-16
EP2603530B1 (fr) 2017-11-08
AR082629A1 (es) 2012-12-19
WO2012020006A3 (fr) 2012-04-12
CL2013000369A1 (es) 2014-08-08
MX358859B (es) 2018-09-05
US20160060356A1 (en) 2016-03-03
WO2012020006A2 (fr) 2012-02-16
PH12017501417A1 (en) 2020-07-13
US20200079873A1 (en) 2020-03-12
LT2603530T (lt) 2018-01-25
JP2018099120A (ja) 2018-06-28
MY175341A (en) 2020-06-19
AU2011288487B2 (en) 2015-10-01
KR20130066669A (ko) 2013-06-20
SI2603530T1 (en) 2018-02-28
SG187746A1 (en) 2013-03-28
CR20180142A (es) 2018-04-05
CR20130038A (es) 2013-04-29
HUE036077T2 (hu) 2018-06-28
TWI599578B (zh) 2017-09-21
ZA201600551B (en) 2018-05-30
CO6670523A2 (es) 2013-05-15
KR20150039890A (ko) 2015-04-13
IL224355B (en) 2019-03-31
KR101673653B1 (ko) 2016-11-08
EA201300239A1 (ru) 2013-08-30
ECSP13012440A (es) 2013-05-31
US10253110B2 (en) 2019-04-09
MX2013001268A (es) 2013-04-10
PE20131209A1 (es) 2013-10-25
JP2015180632A (ja) 2015-10-15
UA112416C2 (uk) 2016-09-12
JP2020141674A (ja) 2020-09-10
JP7017599B2 (ja) 2022-02-08
EA034742B1 (ru) 2020-03-16
JP5793568B2 (ja) 2015-10-14
CN103154038A (zh) 2013-06-12
EP3333194B1 (fr) 2021-03-17
HRP20172004T1 (hr) 2018-02-09
JP2013542714A (ja) 2013-11-28
TW201634480A (zh) 2016-10-01
US20120128591A1 (en) 2012-05-24
TW201206477A (en) 2012-02-16
EA037977B1 (ru) 2021-06-18
US20220281995A1 (en) 2022-09-08
PE20171512A1 (es) 2017-10-20
BR112013003361B8 (pt) 2022-01-25
EP2603530A2 (fr) 2013-06-19
US10577429B2 (en) 2020-03-03
AR117658A2 (es) 2021-08-25
TWI556827B (zh) 2016-11-11
EA201790309A1 (ru) 2017-06-30

Similar Documents

Publication Publication Date Title
MA34519B1 (fr) Anticorps anti-fap et procédés d'utilisation
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA34488B1 (fr) Composition pesticides
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
MA38632B1 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
CL2016000344A1 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
MY160552A (en) Low protein infant formula with increased essential amino acids
MA33551B1 (fr) Anticorps anti-egfl1 humanises, et procedes d'utilisation correspondants
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MA35898B1 (fr) Anticorps anti-lrp5 et leurs procédés d'utilisation
UA110103C2 (uk) Модифікований туберкульозний антиген
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
MA34541B1 (fr) Compositions d'anticorps et procédés d'utilisation
MY161868A (en) Anti-bv8 antibodies and uses thereof
MX2012009564A (es) ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8.
FR2968561B1 (fr) Utilisation d'un anticorps dirige contre une proteine membranaire
MA35947B1 (fr) Anticorps et immunoconjugués anti-lgr5
MA38105A1 (fr) Immunoglobulines hétérodimères
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors